최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0675089 (2008-08-27) |
등록번호 | US-9422363 (2016-08-23) |
국제출원번호 | PCT/US2008/074470 (2008-08-27) |
§371/§102 date | 20100421 (20100421) |
국제공개번호 | WO2009/032693 (2009-03-12) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 373 |
The present invention provides methods for using synthetic apolipoprotein E (ApoE)-mimicking peptides. Also disclosed are methods for using synthetic apolipoprotein E (ApoE)-mimicking peptides to reduce plasma glucose levels. Methods of using the disclosed apolipoprotein E (ApoE)-mimicking peptides
The present invention provides methods for using synthetic apolipoprotein E (ApoE)-mimicking peptides. Also disclosed are methods for using synthetic apolipoprotein E (ApoE)-mimicking peptides to reduce plasma glucose levels. Methods of using the disclosed apolipoprotein E (ApoE)-mimicking peptides to treat diabetes and diabetic complications are also disclosed.
1. A method of decreasing the concentration of plasma glucose in a subject with diabetes or insulin resistance, comprising: administering a synthetic apolipoprotein E-mimicking peptide to the subject with diabetes or insulin resistance, wherein the peptide consists of a receptor binding domain of ap
1. A method of decreasing the concentration of plasma glucose in a subject with diabetes or insulin resistance, comprising: administering a synthetic apolipoprotein E-mimicking peptide to the subject with diabetes or insulin resistance, wherein the peptide consists of a receptor binding domain of apolipoprotein E and a lipid-associating peptide, wherein said receptor binding domain is covalently linked to said lipid-associating peptide, wherein the receptor binding domain contains an acetyl group on the N-terminus and the lipid-associating peptide contains an amide group on the C-terminus, whereby the concentration of plasma glucose in the subject with diabetes or insulin resistance decreases. 2. The method of claim 1, wherein the synthetic apolipoprotein E-mimicking peptide comprises a sequence selected from the group consisting of SEQ ID NOs: 11-14, 18-57, 60, 61, and 62-103. 3. The method of claim 1, wherein the receptor binding domain peptide comprises a sequence selected from the group consisting of SEQ ID NOs: 1-2, 3, 5-10, 15, and 58. 4. The method of claim 3, wherein the lipid-associating peptide is model class A amphipathic helical peptide 18A. 5. The method of claim 1, wherein said lipid-associating peptide comprises a sequence selected from the group consisting of SEQ ID NOs: 4, 16, 17, and 59. 6. The method of claim 1, wherein the synthetic apolipoprotein E-mimicking peptide is administered in a composition comprising a pharmaceutically acceptable carrier. 7. The method of claim 1, wherein the subject has diabetes. 8. The method of claim 1, wherein the receptor binding domain peptide comprises the sequence of SEQ ID NO: 1 and the lipid-associating peptide comprises the sequence of SEQ ID NO: 4. 9. The method of claim 1, wherein the receptor binding domain peptide comprises the sequence of SEQ ID NO: 3 and the lipid-associating peptide comprises the sequence of SEQ ID NO: 4. 10. The method of claim 1, wherein the receptor binding domain peptide comprises the sequence of SEQ ID NO: 15 and the lipid-associating peptide comprises the sequence of SEQ ID NO: 4. 11. The method of claim 1, wherein the receptor binding domain peptide comprises the sequence of SEQ ID NO: 1 and the lipid-associating peptide comprises the sequence of SEQ ID NO: 17. 12. The method of claim 1, wherein the receptor binding domain peptide comprises the sequence of SEQ ID NO: 3 and the lipid-associating peptide comprises the sequence of SEQ ID NO: 17. 13. The method of claim 1, wherein the receptor binding domain peptide comprises the sequence of SEQ ID NO: 15 and the lipid-associating peptide comprises the sequence of SEQ ID NO: 17.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.